14.56
14.56 (0%)
As of Feb 14, 2025
Myriad Genetics Inc [MYGN]
Source:
Company Overview
Myriad Genetics Inc is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. We develop and offer molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower health care costs.
| Country | United States |
| Headquarters | salt lake city, utah |
| Phone Number | (801) 584-3600 |
| Industry | manufacturing |
| CEO | Paul J. Diaz |
| Website | www.myriad.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $837.6 |
| Operating Profit | $-123.5 |
| Net Income | $-127.3 |
| Net Cash | $-29 |
Profit Ratios
| Gross Margin | $585.4 |
| Operating Margin | -14.7 |
| Profit as % of Revenues | -459.9% |
| Profit as % of Assets | -11.7% |
| Profit as % of Stockholder Equity | -18.2% |
Management Effectiveness
| Return on Equity | -18.2% |
| Return on Assets | -12.4% |
| Turnover Ratio | 77.1% |
| EBITA | $-123.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,027.6 |
| Total Liabilities | $326.5 |
| Operating Cash Flow | $-8.7 |
| Investing Cash Flow | $-11.9 |
| Financing Cash Flow | $-7.4 |
